Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 or QL1604 with Bevacizumab in Advanced HCC
NCT05603039Phase 2Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iparomlimab in hepatocellular carcinoma (HCC) (3 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Objective Remission Rate up to 1 year and Safety and Adverse Events up to 1 year. Status: unknown.
02
Drugs
iparomlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05603039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603039.